European Society for Medical Oncology Targeted Anticancer Therapies Asia Congress (ESMO TAT Asia) 2025
Hong Kong 18 July 2025 - 20 July 2025
Can gut microbiome composition predict response to pembrolizumab +/- chemo in treatment-naïve mNSCLC?
23 Sep 2025
byNatalia Reoutova
Research findings from Yonsei Cancer Center in South Korea, presented at European Society for Medical Oncology Targeted Anticancer Therapies Asia Congress (ESMO TAT Asia) 2025, suggest a correlation between butyrate-producing Faecalibacterium enrichment and clinical response to pembrolizumab with or without chemotherapy in treatment-naïve patients with metastatic non-small-cell lung cancer (mNSCLC).